A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities

被引:1
作者
Ribeiro, Ines [1 ,2 ]
Batel Marques, Francisco [1 ,3 ]
Mendes, Diogo [1 ]
Alves, Carlos [1 ,3 ]
机构
[1] CHAD Ctr Hlth Technol Assessment & Drug Res, AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal
[2] Univ Coimbra, Fac Pharm, Coimbra, Portugal
[3] Univ Coimbra, Fac Pharm, Lab Social Pharm & Publ Hlth, Coimbra, Portugal
关键词
Systematic review; cost-utility; ophthalmology; utilities; COST-EFFECTIVENESS ANALYSIS; VERTEPORFIN PHOTODYNAMIC THERAPY; DIABETIC MACULAR EDEMA; VALUE-BASED MEDICINE; POLLEN INDUCED RHINOCONJUNCTIVITIS; RETINAL VEIN OCCLUSION; QUALITY-OF-LIFE; DRY EYE DISEASE; NONINFECTIOUS INTERMEDIATE; INTRAVITREAL AFLIBERCEPT;
D O I
10.1080/09286586.2020.1792938
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To characterize the techniques used to derive health-state utilities (HSU) in the cost-utility studies (CUS) of ophthalmic drugs. Methods A systematic review was conducted in Pubmed/Embase until October 2019. CUS evaluating ophthalmic drugs were included. Therapeutic area, technique to derive HSU and sources of HSU were extracted. It was assessed if the HSU and the other parameters of CUS were collected from the same population. The techniques to derive HSU used in the CUS were compared to the techniques recommended by the country-specific economic evaluation guidelines. Results Seventy CUS were included. Forty-three (61.4%) used direct techniques to derive HSU, 19 (27.1%) used indirect, 1 (1.4%) used direct and indirect and the remaining (n = 7; 10.0%) used other or unknown techniques. Twelve (17.1%) CUS collected the HSU and the other parameters from the same population: nine (12.9%) retrieved utility data from experimental studies, two (2.9%) from observational and one (1.4%) from other sources. Forty-eight (68.6%) CUS collected the HSU and the other parameters from different populations: eight (11.4%) retrieved utility data from experimental studies, 33 (47.1%) from observational, one (1.4%) from both experimental and observational and six (8.6%) from other sources. It was not possible to identify the population from whom data were obtained in 10 (14.3%) CUS. Eleven (15.7%) CUS followed the recommendations of guidelines, 21 (30.0%) did not follow and for 38 (54.3%), it was not possible to assess. Conclusion Choosing different techniques to derive HSU may result in different results, which can preclude the comparison between cost-utility studies.
引用
收藏
页码:325 / 338
页数:14
相关论文
共 50 条
  • [41] Health economic modelling in Cystic Fibrosis: A systematic review
    Mohindru, Bishal
    Turner, David
    Sach, Tracey
    Bilton, Diana
    Carr, Siobhan
    Archangelidi, Olga
    Bhadhuri, Arjun
    Whitty, Jennifer A.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (04) : 452 - 460
  • [42] A systematic review of empirical and simulation studies evaluating the health impact of transportation interventions
    Stankov, Ivana
    Garcia, Leandro M. T.
    Mascolli, Maria Antonietta
    Montes, Felipe
    Meisel, Jose D.
    Gouveia, Nelson
    Sarmiento, Olga L.
    Rodriguez, Daniel A.
    Hammond, Ross A.
    Caiaffa, Waleska Teixeira
    Roux, Ana V. Diez
    ENVIRONMENTAL RESEARCH, 2020, 186
  • [43] A systematic review of health economic evaluations of vaccines in Brazil
    Christovam Sartori, Ana Marli
    Rozman, Luciana Martins
    Decimoni, Tassia Cristina
    Leandro, Roseli
    Dutilh Novaes, Hillegonda Maria
    de Soarez, Patricia Coelho
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1454 - 1465
  • [44] Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies
    Oppong, Raymond
    Jowett, Sue
    Roberts, Tracy E.
    PLOS ONE, 2015, 10 (06):
  • [45] Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data
    Hatswell, Anthony J.
    Burns, Darren
    Baio, Gianluca
    Wadelin, Frances
    HEALTH ECONOMICS, 2019, 28 (05) : 653 - 665
  • [46] EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review
    Golicki, Dominik
    Jaskowiak, Katarzyna
    Wojcik, Alicja
    Mlynczak, Katarzyna
    Dobrowolska, Iwona
    Gawronska, Andzelika
    Basak, Grzegorz
    Snarski, Emilian
    Holownia-Voloskova, Malwina
    Jakubczyk, Michal
    Niewada, Maciej
    VALUE IN HEALTH, 2020, 23 (07) : 953 - 968
  • [47] Thurstone scaling revealed systematic health-state valuation differences between patients with dementia and proxies
    Arons, Alexander M. M.
    Krabbe, Paul F. M.
    Scholzel-Dorenbos, Carla J. M.
    van der Wilt, Gert Jan
    Rikkert, Marcel G. M. Olde
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2012, 65 (08) : 897 - 905
  • [48] A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistance
    Ahmed, Waqas
    Longworth, Louise
    Oluboyede, Yemi
    Cain, Peter
    Amorosi, Stacey L.
    Hill, Sarah
    Hirji, Ishan
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2024, 22 (01)
  • [49] A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis
    de Graaff, Barbara
    Neil, Amanda
    Sanderson, Kristy
    Si, Lei
    Yee, Kwang Chien
    Palmer, Andrew J.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2015, 13 (05) : 469 - 483
  • [50] Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review
    Lemmon, Elizabeth
    Hanna, Catherine R.
    Hall, Peter
    Morris, Eva J. A.
    EUROPEAN JOURNAL OF CANCER CARE, 2021, 30 (05)